---
schema_version: "secwatch.filing_event.v1"
accession: "0001420720-24-000036"
form_type: "8-K"
ticker: "IBIO"
cik: "0001420720"
company_name: "iBio, Inc."
filed_at: "2024-09-20T23:59:59+00:00"
generated_at: "2026-05-31T02:45:53.809203+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# iBio FY2024 net loss $24.9M; revenue $0.2M; auditor raises going concern

## Summary
- Net loss narrowed to $24.9M from $65M YoY; R&D expense fell $5.1M, G&A fell $7.3M.
- Cash, equivalents, restricted cash $14.4M at June 30, 2024; going concern warning in audit opinion.
- Sold Texas manufacturing facility to Texas A&M for $8.5M, eliminating $13.2M secured debt.
- Sold PD-1 asset to Otsuka for $1M upfront plus up to $52.5M milestones; entered AstralBio collaboration.
- Raised ~$24M in equity (public offer $4.5M, PIPE $15M, warrant exercise $4.5M) after 1:20 reverse split.

## SEC filing metadata
- accession: 0001420720-24-000036
- form_type: 8-K
- ticker: IBIO
- cik: 0001420720
- company_name: iBio, Inc.
- filed_at: 2024-09-20T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1420720/000142072024000036/0001420720-24-000036-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1420720/000142072024000036/ibio-20240630x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001420720-24-000036
- JSON: https://secwatch.observer/filing/0001420720-24-000036.json
- Plain text: https://secwatch.observer/filing/0001420720-24-000036.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.